AR053452A1 - Derivados de benzo hidrogenado (c)tiofeno - Google Patents
Derivados de benzo hidrogenado (c)tiofenoInfo
- Publication number
- AR053452A1 AR053452A1 ARP060101156A ARP060101156A AR053452A1 AR 053452 A1 AR053452 A1 AR 053452A1 AR P060101156 A ARP060101156 A AR P060101156A AR P060101156 A ARP060101156 A AR P060101156A AR 053452 A1 AR053452 A1 AR 053452A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrrolidin
- carboxylic acid
- propoxy
- hydroxy
- ethyl
- Prior art date
Links
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title 1
- -1 2,3-dihydroxypropyl Chemical group 0.000 abstract 22
- 125000005907 alkyl ester group Chemical group 0.000 abstract 18
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 12
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 abstract 12
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- NDUWNWVXAYLZSO-UHFFFAOYSA-N pyrrolidin-2-ol Chemical compound OC1CCCN1 NDUWNWVXAYLZSO-UHFFFAOYSA-N 0.000 abstract 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 abstract 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 abstract 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 1
- 125000004848 alkoxyethyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 1
- 125000005157 alkyl carboxy group Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 230000000877 morphologic effect Effects 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002904 solvent Chemical class 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- 150000003577 thiophenes Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Dichos compuestos actuan particularmente como agentes inmunosupresores. Reivindicacion 1: Un compuesto seleccionado del grupo que consiste en tiofenos de la formula (1) en la cual A representa-CONH-CH2-, - CO-CH=CH-, -CO-CH2CH2-, -CO-CH2-O-, -CO-CH2- NH-, los compuestos de formulas (2); R1 representa H, alquilo C1-5, alcoxi C1-5 o halogeno; R2 representa H, alquilo C1-5, alcoxi C1-5, trifluormetilo, trifluormetoxi, o halogeno; R3 representa H, hidroxialquilo C1-5, 2,3-dihidroxipropilo, di- (hidroxi-alquilo C1-5)-alquilo C1-5, -CH2-(CH2)k-NR31R32, (ácido azetidin-3-carboxílico)-1-il-metilo, (éster de alquilo C1-5 de ácido azetidin-3-carboxílico)-1-il-metilo, 2-[(-ácido azetidin-3-carboxílico)-1-il-etilo, 2-[(éster de alquilo C1-5 de ácido azetidin-3-carboxílico)-1-il]-etilo, 3-[(ácido azetidin-3-carboxílico)-1-il]-propilo, 3-[(éster de alquilo C1-5 de ácido azetidin-3- carboxílico)-1-il]-propilo, (ácido pirrolidin-3-carboxílico)-1-il-metilo, (éster de alquilo C1-5 de ácido pirrolidin-3-carboxílico)-1-il-metilo, (ácido pirrolidin-2-carboxílico)-1-il-metilo, (éster de alquilo C1-5 de ácido pirrolidin-2-carboxílico)-1-il-metilo, 2-[(-ácido pirrolidin-3- carboxílico)-1-il]-etilo, 2-[(éster de alquilo C1-5 de ácido pirrolidin-3-carboxílico)-1-il]-etilo, 2-[(ácido pirrolidin-2-carboxílico)-1-il]-etilo, 2-[(éster de alquilo C1-5 de ácido pirrolidin-2-carboxílico)-1-il]-etilo, 3-[(ácido pirrolidin-3-carboxílico)-1-il]-propilo, 3-[(éster de alquilo C1-5 de ácido pirrolidin-3-carboxílico)-1-il]-propilo, 3-[(ácido pirrolidin-2-carboxílico)-1-il]-propilo, 3-[(éster de alquilo C1-5 de ácido pirrolidin-2-carboxílico)-1-il]-propilo, -CH2-(CH2)n-CONR31R32, -CO-NHR31, 1-(1-(3-carboxi-azetidinil))-2-acetilo, 1-(1-(2- carboxi- pirrolidinil))-2-acetilo, 1-(1-(3-carboxi-pirrolidinil))-2-acetilo, 1-(1-(3-carboxi-azetidinil))-3-propionilo, 1-(1-(2-carboxi-pirrolidinil))-3- propionilo, 1-(1-(3-carboxi-pirrolidinil))-3-propionilo, -(CH2)nCH(OH)-CH2-NR31R32, hidroxi, alcoxi C1-5, fluoralcoxi C1-5, hidroxialcoxi C2-5, di-(hidroxialquilo C1-5)-alcoxi C1-5, 1-glicerilo, 2-glicerilo, 2-hidroxi-3-metoxi-propoxi, -OCH2-(CH2)m-NR31R32, 2-pirrolidin-1-il- etoxi, 3-pirrolidin-1-il-propoxi, 2-piperazin-1-il-etoxi, 2-[4- (alquilo C1-5)-piperazin-1-il]-etoxi, 2-[4-(2-hidroxi-etil)-piperazin-1-il]-etoxi, 3-piperazin-1-il-propoxi, 3-[4-(alquilo C1-5)-piperazin-1-il]-propoxi, 3-[4-(2-hidroxi-etil)-piperazin-1-il]-propoxi, 2-morfolin-4-il-etoxi, 3- morfolin-4-il-propoxi, 2-[(ácido azetidin-3-carboxílico)-1-il]-etoxi, 2-[(éster de alquilo C1-5 de ácido azetidin-3-carboxílico)-1-il]-etoxi, 2-[(ácido pirrolidin-3-carboxílico)-1-il]-etoxi, 2-[(éster de alquilo C1-5 de ácido pirrolidin-3-carboxílico)-1-il]-etoxi, 2- [(ácido pirrolidin-2- carboxílico)-1-il]-etoxi, 2-[(éster de alquilo C1-5 de ácido pirrolidin-2-carboxílico)-1-il]-etoxi, 2-[(2-hidroxi-pirrolidin)-1-il]-etoxi, 2-[(3- hidroxi-pirrolidin)-1-il]-etoxi, 3-[(ácido azetidin-3-carboxílico)-1-il]-propoxi, 3- [(éster de alquilo C1-5 de ácido azetidin-3-carboxílico)-1- il]-propoxi, 3-[(ácido pirrolidin-3-carboxílico)-1-il]-propoxi, 3-[(éster de alquilo C1-5 de ácido pirrolidin-3-carboxílico)-1-il]-propoxi, 3-[(ácido pirrolidin-2-carboxílico)-1-il]-propoxi, 3-[(éster de alquilo C1-5 de ácido pirrolidin-2-carboxílico)-1-il]-propoxi, 3-[(2-hidroxi- pirrolidin)-1-il]-propoxi, 3-[(3-hidroxi-pirrolidin)-1-il]-propoxi, 2-amino-3-hidroxi-2-hidroximetil-propoxi, -O-CH2-CONR31R32, 1-(1-(3- carboxi-azetidinil))-1- oxo-2-etoxi, 1-(1-(ácido pirrolidin-2-carboxílico)-1-il)-1-oxo-2-etoxi, 1-(1-(ácido pirrolidin-3-carboxílico)-1-il)-1- oxo-2-etoxi, 3-carbamoil-propoxi, 3-(alquilcarbamoilo C1-5)propoxi, 3-(2-hidroxietilcarbamoil)propoxi, -OCH2-CH(OH)-CH2-NR31R32, 3- [(ácido azetidin-3-carboxílico)-1-il]-2-hidroxipropoxi, 3-[(éster de alquilo C1-5 de ácido azetidin-3-carboxílico)-1-il]-2-hidroxipropoxi, 2- hidroxi-3-[(ácido pirrolidin-3-carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(éster de alquilo C1-5 de ácido pirrolidin-3-carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(ácido pirrolidin-2-carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(éster de alquilo C1-5 de ácido pirrolidin-2-carboxílico)-1-il]- propoxi, 2-hidroxi-3-[(2-hidroxi-pirrolidin)-1-il]-propoxi, 2-hidroxi- 3-[(3-hidroxi-pirrolidin)-1-il]propoxi, 2-hidroxi-3-pirrolidin-1-il-propoxi, 2-hidroxi-3-piperazin-1-il-propoxi, 2-hidroxi-3-[4-(alquilo C1-5)-piperazin-1-il]-propoxi, 2-hidroxi-3-[4-(2-hidroxi-etil)-piperazin-1-il]- propoxi, 2-hidroxi-3-morfolin-4- il-propoxi, -NR31R32, -NHCO-R31, -CH2-(CH2)k-NHSO2R33, -(CH2)nCH(OH)-CH2-NHSO2R33, - OCH2-(CH2)m-NHSO2R33, -OCH2-CH(OH)-CH2-NHSO2R33, -CH2-(CH2)k-NHCOR34, -(CH2)nCH(OH)-CH2-NHCOR34, -OCH2-(CH2)m- NHCOR34, -OCH2-CH(OH)-CH2-NHCOR34, o SO2NHR31; R31 representa H, metilo, etilo, 1-propilo, 2-propilo, 2-hidroxietilo, 2-hidroxi-1- hidroximetil-etilo, 2,3-dihiroxipropilo, 2-alcoxietilo C1-5, 3-hidroxipropilo, 3-alcoxipropilo C1-5, 2-aminoetilo, 2-(alquilamino C1-5)etilo, 2-(di-(alquilo C1- 5)amino)etilo, carboximetilo, alquilcarboximetilo C1-5, 2-carboxietilo, o 2-(alquilcarboxi C1-5)etilo; R32 representa H, metilo, o etilo; R33 representa metilo, etilo, propilo, isopropilo, butilo, 2-hidroxietilo, 2-metoxietilo, metilamino, etilamino, propilamino, isopropilamino, n-butilamino, o dimetilamino; R34 representa hidroximetilo, hidroxietilo, aminometilo, metilaminometilo, dimetilaminometilo, aminoetilo, 2-metilamino-etilo, o 2-dimetilamino-etilo; k representa el numero entero 1, 2 o 3;m representa el numero entero 1 o 2; n representa 0, 1, o 2; y R4 representa H, alquilo C1-5, o halogeno; R5 representa metilo o etilo; R6 representa metilo o etilo; o R5 y R6 conjuntamente forman un anillo carboxílico de 3, 4, o 5 miembros; y R7 representa H, metilo, etilo, n-propilo, isopropilo, trifluormetilo, hidroximetilo, metoximetilo, metoxi, metiltio, hidroxicarbonilo, aminocarbonilo, mono- o di-(alquilo C1-5) aminocarbonilo, amino, mono- o di-(alquilo C1-5)amino, y los isomeros configuraciones tales como los enantiomeros opticamente puros, mezclas de enantiomeros tales como racematos, diastereomeros, mezclas de diastereomeros, racematos diastereoméricos, y mezclas de racematos diastereoméricos, así como también sales y complejos de solventes de dichos compuestos y formas morfologicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2005003071 | 2005-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053452A1 true AR053452A1 (es) | 2007-05-09 |
Family
ID=36592888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101156A AR053452A1 (es) | 2005-03-23 | 2006-03-23 | Derivados de benzo hidrogenado (c)tiofeno |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7723378B2 (es) |
| EP (1) | EP1863787B1 (es) |
| JP (1) | JP5047941B2 (es) |
| KR (1) | KR101382733B1 (es) |
| CN (1) | CN101180290B (es) |
| AR (1) | AR053452A1 (es) |
| AT (1) | ATE510831T1 (es) |
| AU (1) | AU2006226018B2 (es) |
| BR (1) | BRPI0609515A8 (es) |
| CA (1) | CA2602474C (es) |
| CY (1) | CY1111767T1 (es) |
| DK (1) | DK1863787T3 (es) |
| ES (1) | ES2365747T3 (es) |
| HR (1) | HRP20110613T1 (es) |
| IL (1) | IL186148A (es) |
| MX (1) | MX2007011670A (es) |
| MY (1) | MY147949A (es) |
| NO (1) | NO340192B1 (es) |
| NZ (1) | NZ562562A (es) |
| PL (1) | PL1863787T3 (es) |
| PT (1) | PT1863787E (es) |
| RU (1) | RU2412179C2 (es) |
| SI (1) | SI1863787T1 (es) |
| TW (1) | TWI402262B (es) |
| WO (1) | WO2006100631A1 (es) |
| ZA (1) | ZA200709088B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4678139B2 (ja) * | 2004-05-10 | 2011-04-27 | トヨタ自動車株式会社 | 自動車の暖房制御システム |
| WO2006010379A1 (en) * | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| RU2404178C2 (ru) * | 2005-03-23 | 2010-11-20 | Актелион Фармасьютиклз Лтд | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
| RU2007138878A (ru) | 2005-03-23 | 2009-04-27 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
| RU2008101805A (ru) * | 2005-06-24 | 2009-07-27 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные тиофена |
| AR057894A1 (es) * | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| JP5063615B2 (ja) | 2006-01-24 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規ピリジン誘導体 |
| KR101470659B1 (ko) | 2006-09-07 | 2014-12-08 | 액테리온 파마슈티칼 리미티드 | 면역조절제로서 피리딘-4-일 유도체 |
| TWI408139B (zh) * | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| MX2009002234A (es) * | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
| RU2442780C2 (ru) | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Фенильные производные и их применение в качестве иммуномодуляторов |
| DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| EP2222667B1 (en) * | 2007-12-10 | 2013-02-20 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as agonists of s1p1/edg1 |
| PE20091339A1 (es) * | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| CA2714665A1 (en) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridine compounds |
| JP5435745B2 (ja) * | 2008-03-07 | 2014-03-05 | アクテリオン ファーマシューティカルズ リミテッド | 免疫調節剤としてのピリジン−２−イル誘導体 |
| AR070842A1 (es) | 2008-03-17 | 2010-05-05 | Actelion Pharmaceuticals Ltd | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 |
| SI2326621T1 (sl) | 2008-07-23 | 2016-10-28 | Arena Pharmaceuticals, Inc. | Substituirani derivati 1,2,3,4-tetrahidrociklopenta(b)indol-3-il)ocetne kisline, uporabni pri zdravljenju avtoimunskih in vnetnih motenj |
| NZ591001A (en) | 2008-08-27 | 2012-11-30 | Arena Pharm Inc | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| US8404672B2 (en) | 2009-01-23 | 2013-03-26 | Bristol-Meyers Squibb Company | Substituted heterocyclic compounds |
| JP5036923B1 (ja) | 2009-07-16 | 2012-09-26 | アクテリオン ファーマシューティカルズ リミテッド | ピリジン−４−イル誘導体 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| JP5869579B2 (ja) | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 |
| EP2665720B1 (en) | 2011-01-19 | 2015-06-10 | Actelion Pharmaceuticals Ltd. | 2-methoxy-pyridin-4-yl derivatives |
| CA2877826C (en) | 2012-07-09 | 2016-08-16 | Lupin Limited | Tetrahydroquinazolinone derivatives as parp inhibitors |
| HRP20200883T1 (hr) | 2012-08-17 | 2020-09-04 | Actelion Pharmaceuticals Ltd. | Postupak za pripremanje (2z,5z)-5-(3-kloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međuproizvodi koji se koriste u navedenom postupku |
| CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| PT3298008T (pt) | 2015-05-20 | 2020-02-03 | Idorsia Pharmaceuticals Ltd | Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6- metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metilfenoxi}- propano-1,2¿diol |
| US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
| AU2016284162A1 (en) | 2015-06-22 | 2018-02-01 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| WO2019236757A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| KR20240018890A (ko) | 2022-08-03 | 2024-02-14 | 이진수 | 절개선을 갖는 종이 원단의 연신 특성을 이용한 과일 트레이 제조방법 및 이로부터 제조된 친환경 과일 트레이 |
| KR20240078837A (ko) | 2022-11-28 | 2024-06-04 | 이진수 | 폐지를 활용한 임산물 트레이 제조방법 및 이로부터 제조된 친환경 임산물 트레이 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1989480A (en) * | 1932-06-27 | 1935-01-29 | Associated Patents Inc | Process of preparing cereal foods |
| US2000615A (en) * | 1935-03-04 | 1935-05-07 | Chester H Roth | Hosiery |
| FR2599740B1 (fr) * | 1986-06-05 | 1988-08-12 | Rhone Poulenc Sante | Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant |
| US4963557A (en) | 1987-09-28 | 1990-10-16 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
| WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| ZA917371B (en) | 1990-09-20 | 1992-06-24 | Merrell Dow Pharma | Calcium uptake inhibitors |
| DE19642451A1 (de) * | 1996-10-15 | 1998-04-16 | Merck Patent Gmbh | Aminothiophencarbonsäureamide |
| EP1070080A4 (en) | 1998-03-09 | 2004-12-29 | Smithkline Beecham Corp | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS |
| GB9808665D0 (en) * | 1998-04-23 | 1998-06-24 | Merck Sharp & Dohme | Therapeutic compounds |
| EP1268486A2 (en) * | 2000-03-31 | 2003-01-02 | Takeda Chemical Industries, Ltd. | Fused heterocyclic derivatives, their production and use |
| WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| WO2003062252A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN1788008A (zh) | 2003-05-15 | 2006-06-14 | 麦克公司 | 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑 |
| GB0313677D0 (en) * | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| AU2004277947A1 (en) * | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| RU2007138878A (ru) * | 2005-03-23 | 2009-04-27 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
| RU2404178C2 (ru) * | 2005-03-23 | 2010-11-20 | Актелион Фармасьютиклз Лтд | Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1 |
| AR057894A1 (es) * | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| JP5063615B2 (ja) * | 2006-01-24 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規ピリジン誘導体 |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
-
2006
- 2006-03-20 MX MX2007011670A patent/MX2007011670A/es active IP Right Grant
- 2006-03-20 NZ NZ562562A patent/NZ562562A/en not_active IP Right Cessation
- 2006-03-20 SI SI200631088T patent/SI1863787T1/sl unknown
- 2006-03-20 HR HR20110613T patent/HRP20110613T1/hr unknown
- 2006-03-20 AT AT06727679T patent/ATE510831T1/de active
- 2006-03-20 DK DK06727679.0T patent/DK1863787T3/da active
- 2006-03-20 BR BRPI0609515A patent/BRPI0609515A8/pt active Search and Examination
- 2006-03-20 JP JP2008502538A patent/JP5047941B2/ja not_active Expired - Fee Related
- 2006-03-20 RU RU2007138875/04A patent/RU2412179C2/ru not_active IP Right Cessation
- 2006-03-20 CA CA2602474A patent/CA2602474C/en not_active Expired - Fee Related
- 2006-03-20 KR KR1020077024309A patent/KR101382733B1/ko not_active Expired - Fee Related
- 2006-03-20 AU AU2006226018A patent/AU2006226018B2/en not_active Ceased
- 2006-03-20 PT PT06727679T patent/PT1863787E/pt unknown
- 2006-03-20 ES ES06727679T patent/ES2365747T3/es active Active
- 2006-03-20 WO PCT/IB2006/050845 patent/WO2006100631A1/en not_active Ceased
- 2006-03-20 PL PL06727679T patent/PL1863787T3/pl unknown
- 2006-03-20 US US11/909,429 patent/US7723378B2/en not_active Expired - Fee Related
- 2006-03-20 EP EP06727679A patent/EP1863787B1/en active Active
- 2006-03-20 CN CN2006800172389A patent/CN101180290B/zh not_active Expired - Fee Related
- 2006-03-21 MY MYPI20061242A patent/MY147949A/en unknown
- 2006-03-22 TW TW095109919A patent/TWI402262B/zh not_active IP Right Cessation
- 2006-03-23 AR ARP060101156A patent/AR053452A1/es unknown
-
2007
- 2007-09-20 IL IL186148A patent/IL186148A/en not_active IP Right Cessation
- 2007-10-17 NO NO20075299A patent/NO340192B1/no not_active IP Right Cessation
- 2007-10-22 ZA ZA200709088A patent/ZA200709088B/xx unknown
-
2010
- 2010-03-29 US US12/749,180 patent/US8039644B2/en not_active Expired - Fee Related
-
2011
- 2011-08-24 CY CY20111100806T patent/CY1111767T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053452A1 (es) | Derivados de benzo hidrogenado (c)tiofeno | |
| AR055751A1 (es) | Derivados de tiofeno y composiciones farmaceuticas | |
| AR053449A1 (es) | Derivados de tiofeno agonistas del receptor s1p1/edg1 | |
| AR057894A1 (es) | Derivados de tiofeno | |
| CO2019003349A2 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR061841A1 (es) | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. | |
| AR010740A1 (es) | Compuestos derivados de pirimidina biciclica condensada, composicion farmaceutica que los contiene y procedimiento de tratamiento que utilizadichos compuestos | |
| AR058956A1 (es) | Derivados de tiofeno agonistas de receptores s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. | |
| AR070819A1 (es) | Derivados aminometil benceno | |
| UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| AR082891A1 (es) | Di-azetidinil diamidas como inhibidores de monoacilglicerol lipasas | |
| ECSP099728A (es) | Compuestos amino-heterocíclicos | |
| AR050273A1 (es) | Derivados de tiofeno como agentes inmunosupresores | |
| MX2023010377A (es) | Derivado policiclico de carbamoilpiridona. | |
| AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
| PE20081496A1 (es) | Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1 | |
| CR11181A (es) | Derivados de ftalazinona | |
| PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
| CN105733562A (zh) | 一系列芴衍生物发光材料 | |
| ATE487684T1 (de) | Ringkondensierte aromatische verbindung und lichtemittierende einrichtung unter verwendung derselben | |
| AR070858A1 (es) | Derivados piridin-2-ilo | |
| CO6351793A2 (es) | \"derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis | |
| ECSP11010800A (es) | Nuevos derivados de acilaminobenzamida | |
| CR10671A (es) | Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas | |
| CL2020002579A1 (es) | Compuesto de fenoxiurea y un agente de control de plagas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |